Multiple antitumor effects of picropodophyllin in colon carcinoma cell lines: Clinical implications

International Journal of Oncology

Volumn 40, Issue 4, 2012, Pages 1251-1258

  Feng, Xiaoying ^a,b   Aleem, Eiman ^a,c   Lin, Yingbo ^a   Axelson, Magnus ^d   Larsson, Olle ^a   Strömberg, Thomas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c Alexandria University Faculty Of Science   (Egypt)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Colon carcinoma; Insulin like growth factor 1; Insulin like growth factor 1 receptor; Insulin like growth factor 2; Matrix metalloproteinase; Picropodophyllin

Indexed keywords

ANTINEOPLASTIC AGENT; GELATINASE B; MATRILYSIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PICROPODOPHYLLIN; PROTEIN KINASE B; RESAZURIN; SOMATOMEDIN B; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; COLON CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR VOLUME;

ADENOCARCINOMA; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; COLONIC NEOPLASMS; DOWN-REGULATION; HCT116 CELLS; HT29 CELLS; HUMANS; PHOSPHORYLATION; PODOPHYLLOTOXIN; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84863345782     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1281     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
2. Sandhu MS, Dunger DB and Giovannucci EL: Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic inter-actions, and colorectal cancer. J Natl Cancer Inst 94: 972-980, 2002. (Pubitemid 34814726)
3. Center MM, Jemal A, Smith RA and Ward E: Worldwide variations in colorectal cancer. CA Cancer J Clin 59: 366-378, 2009.
4. Ullrich A, Gray A, Tam AW, et al: Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5: 2503-2512, 1986.
5. Navarro M and Baserga R: Limited redundancy of survival signals from the type 1 insulin-like growth factor receptor. Endocrinology 142: 1073-1081, 2001. (Pubitemid 32202816)
6. Belfiore A, Pandini G, Vella V, Squatrito S and Vigneri R: Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer. Biochimie 81: 403-407, 1999.
7. All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ and Larsson O: Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci 43: 1-8, 2002. (Pubitemid 34032432)
8. Xie Y, Skytting B, Nilsson G, Brodin B and Larsson O: Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res 59: 3588-3591, 1999. (Pubitemid 29381857)
9. Sachdev D and Yee D: Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6: 1-12, 2007. (Pubitemid 46206663)
10. Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O and Axelson M: Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 64: 236-242, 2004. (Pubitemid 38114104)
11. Stromberg T, Ekman S, Girnita L, et al: IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 107: 669-678, 2006. (Pubitemid 43076393)
12. Menu E, Jernberg-Wiklund H, Stromberg T, et al: Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 107: 655-660, 2006. (Pubitemid 43076391)
13. Menu E, Jernberg-Wiklund H, De Raeve H, et al: Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int J Cancer 121: 1857-1861, 2007. (Pubitemid 47417307)
14. Yin S, Girnita A, Stromberg T, et al: Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neurooncology 12: 19-27, 2010.
15. Girnita A, All-Ericsson C, Economou MA, et al: The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin Cancer Res 12: 1383-1391, 2006. (Pubitemid 43342532)
16. Ekman S, Frodin JE, Harmenberg J, et al: Clinical phase I study with an Insulin-like growth factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol 50: 441-447, 2011.
17. Midgley R and Kerr D: Colorectal cancer. Lancet 353: 391-399, 1999. (Pubitemid 29088178)
18. Reinmuth N, Fan F, Liu W, et al: Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 82: 1377-1389, 2002. (Pubitemid 35191541)
19. Wu Y, Yakar S, Zhao L, Hennighausen L and LeRoith D: Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 62: 1030-1035, 2002. (Pubitemid 34160283)
20. Sounni NE and Noel A: Membrane type-matrix metalloproteinases and tumor progression. Biochimie 87: 329-342, 2005. (Pubitemid 40387612)
21. Newell KJ, Witty JP, Rodgers WH and Matrisian LM: Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog 10: 199-206, 1994. (Pubitemid 24283035)
22. Barozzi C, Ravaioli M, D'Errico A, et al: Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel. Cancer 94: 647-657, 2002. (Pubitemid 34132292)
23. Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y and Imai K: Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut 45: 252-258, 1999. (Pubitemid 29333775)
24. Nielsen BS, Timshel S, Kjeldsen L, et al: 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 65: 57-62, 1996. (Pubitemid 26027538)
25. Horiuchi S, Yamamoto H, Min Y, Adachi Y, Itoh F and Imai K: Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer. J Pathol 200: 568-576, 2003. (Pubitemid 36987305)
26. Liang CC, Park AY and Guan JL: In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2: 329-333, 2007. (Pubitemid 47040047)
27. Buck E and Mulvihill M: Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Expert Opin Investig Drugs 20: 605-621, 2011.
28. Reinmuth N, Liu W, Fan F, et al: Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res 8: 3259-3269, 2002. (Pubitemid 35155039)
29. Hakam A, Yeatman TJ, Lu L, et al: Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 30: 1128-1133, 1999. (Pubitemid 29480878)
30. Weber MM, Fottner C, Liu SB, Jung MC, Engelhardt D and Baretton GB: Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 95: 2086-2095, 2002. (Pubitemid 35253369)
31. Peters G, Gongoll S, Langner C, et al: IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch 443: 139-145, 2003. (Pubitemid 37056137)
32. Nakamura M, Miyamoto S, Maeda H, et al: Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability. Biochem Biophys Res Commun 333: 1011-1016, 2005. (Pubitemid 40854257)
33. Baserga R: Targeting the IGF-1 receptor: from rags to riches. Eur J Cancer 40: 2013-2015, 2004.
34. Vasilcanu R, Vasilcanu D, Sehat B, et al: Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin. Mol Pharmacol 73: 930-939, 2008. (Pubitemid 351397897)
35. Vasilcanu R, Vasilcanu D, Rosengren L, et al: Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1. Oncogene 27: 1629-1638, 2008. (Pubitemid 351347881)
36. Duan Z, Choy E, Harmon D, et al: Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther 8: 2122-2130, 2009.